ClinicaliQ Trial Snapshot
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies — Active Not Recruiting • Phase II • NCT05885555.
- Ianalumab is tested in adults with hard-to-treat immune thrombocytopenia who've failed previous treatments.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA. Conditions: Primary Immune Thrombocytopenia (ITP) Interventions: Ianalumab Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 41 participants